Exact Sciences (NASDAQ:EXAS) Shares Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Exact Sciences Corporation (NASDAQ:EXAS). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in Exact Sciences stock on March 24th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Exact Sciences Stock Performance

NASDAQ EXAS remained flat at $104.91 during trading on Tuesday. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The stock has a market capitalization of $20.03 billion, a price-to-earnings ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. The business’s fifty day simple moving average is $103.62 and its two-hundred day simple moving average is $90.07. Exact Sciences Corporation has a 52 week low of $38.81 and a 52 week high of $104.98.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The firm had revenue of $878.38 million during the quarter, compared to the consensus estimate of $860.59 million. During the same period in the prior year, the business earned ($0.06) EPS. The company’s revenue for the quarter was up 23.1% compared to the same quarter last year. As a group, sell-side analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Mizuho restated a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research downgraded shares of Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research note on Tuesday, March 24th. Evercore set a $105.00 target price on Exact Sciences and gave the stock an “in-line” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Twenty-one research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $92.13.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new position in shares of Exact Sciences in the fourth quarter worth $26,000. Torren Management LLC acquired a new stake in shares of Exact Sciences during the fourth quarter valued at about $27,000. Westside Investment Management Inc. lifted its stake in shares of Exact Sciences by 100.0% in the third quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock worth $31,000 after acquiring an additional 271 shares during the period. Legacy Capital Wealth Partners LLC acquired a new position in shares of Exact Sciences in the fourth quarter worth approximately $42,000. Finally, Hantz Financial Services Inc. increased its holdings in Exact Sciences by 100.5% in the fourth quarter. Hantz Financial Services Inc. now owns 421 shares of the medical research company’s stock worth $43,000 after purchasing an additional 211 shares in the last quarter. Institutional investors own 88.82% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.